Joined as first finance employee in April 2022 to build team and prepare for NASDAQ IPO, completed Nov 2022. Followed by $130M PIPE at 44% premium April 2024.

Building company from foundation, initial acquisition of assets and public offering, to first product approval and commercial launch.

Inner circle member of team that built Synageva from enterprise value of less than $0.15B in 2011 to successful exit at $9B+ in 2015. Initially leading transformation of Technical Operations (>70% of employees at time). Went on to create new division ground up with incremental portfolio of 12+ rare disease development programs while driving numerous other breakthrough projects, including the Alexion transaction process. Performance rated “Outstanding”.

Turnaround of a global commercial organization, significantly increasing launch excellence, cost efficiency and performance transparency. Reporting to the CEO of GN ReSound, one of the world’s largest providers of hearing aids and audiological instrumentation (3000+ employees). Responsibility for Strategy and Business Development was subsequently added. Reported directly to the chairman for special projects. The GN:DC share price appreciated 450%+ by 2010 and 1500% by 2014, compared to the low point in 2008.

Bottom-line responsible for all Novo Nordisk activities in region of 30+ countries. Hands-on operational experience setting up local presence, leading internal and external sales forces, 10+ launches, 20+ partnerships incl. production, distribution and management of key opinion leaders / top level government officials. Strong profit margin and profit growth delivered along with organizational and strategic turnaround. Distributor contracts revamped across region and SOX/SEC compliance projects implemented. Performance rated “Outstanding”.

Headed the Novo Nordisk finance functions in Latin America through a number of transformations including setting up stock holding affiliates in Mexico and Venezuela, establishing a branch office in Chile, integrating and restructuring an acquired company in Brazil, closing a regional office in Florida and moving the finance, customer service, IT, regulatory and quality functions to Sao Paulo, implementing Quality Mindset and shared services, initiation of USD 200 million production investment project in Brazil as well as a number of product launches and changes of local distributors. Working languages: English, Portuguese, Danish and Spanish. Creating the right team and team spirit was the key to success. Four finance analysts hired were promoted to manager or director level in other areas within Novo Nordisk. [Update: Several are CEOs today.]

Bottom line responsible for all Novo Nordisk activities in 35 countries. The region expanded with 3 new offices and delivered strong profit growth. An important turnaround in performance was produced and a reorganization of the region designed and successfully implemented.

Head of Investor Relations in North America. Did more than 250 external investor meetings and group presentations. Gained understanding of public relations, issue management, corporate governance as well as the pharmaceutical and ingredients industries in general. Responsible for US SEC reporting and compliance (SOX, Form 20F etc). Several IR prizes won during tenure.

Joined Novo Nordisk IR to support the de-merger/IPO of Novozymes (former Novo Nordisk Enzyme Business). This was a unique opportunity to work closely with the new and the old executive management teams on the re-launch of the companies. Assumed after 1 year responsibility for North America.

Responsible for the health care R&D portfolio analysis in Novo Nordisk, providing decision support for top management. Implemented state of the art valuation and decision support models and processes. Gained understanding of the complete value chain. Worked on GLP-1 project that became Victoza, Vegovy, Ozempic etc.

Headed global budgeting and monthly reporting processes. Invented and implemented new controlling tools, several of which became corporate or unit standards. Learned about production economy, the ingredients industry, corporate planning, investment strategy, project management, data warehouse design and team building. Worked with current Novo Nordisk CEO Lars Fruergaard.